# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 71-80 of 567 results.
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Status: Recruiting
Last Changed: Aug 09, 2019
First Received: May 06, 2019
Disease(s): Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Intervention(s): Abexinostat, Ibrutinib
Locations: Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
Memorial Sloan Kettering Westchester, Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
... and 2 other locations.
An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)
Status: Recruiting
Last Changed: Jul 17, 2018
First Received: Feb 03, 2015
Disease(s): B-cell Lymphoma
Locations: Severance Hospital, Seoul, Korea, Republic of
A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 08, 2019
First Received: Oct 12, 2017
Disease(s): B Cell Lymphoma
Intervention(s): Varlilumab
Locations: The Christie NHS Foundation Trust, Manchester, United Kingdom
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Plymouth Hospitals NHS Trust, Plymouth, United Kingdom
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
Status: Recruiting
Last Changed: Feb 26, 2019
First Received: Feb 26, 2019
Disease(s): B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia
Intervention(s): Anti-CD19 CAR-T Cells Injection
Locations: Kunming Yan'an Hospital, Oncology Department, Kunming, Yunnan, China
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
Status: Recruiting
Last Changed: Jul 08, 2019
First Received: Jun 14, 2019
Disease(s): Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Intervention(s): blood sample
Locations: University Hospital Limoges, Limoges, France
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Status: Recruiting
Last Changed: Nov 28, 2018
First Received: Sep 14, 2016
Disease(s): Chronic Lymphocytic Leukemia, B-Cell Lymphoma
Intervention(s): DTRMWXHS-12, DTRM-505, DTRM-555
Locations: Mayo Clinic, Phoenix, Arizona, United States
Yale Cancer Center, New Haven, Connecticut, United States
Mayo Clinic, Jacksonville, Florida, United States
Mayo Clinic, Rochester, Minnesota, United States
Duke University Medical Center, Durham, North Carolina, United States
... and 2 other locations.
A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
Status: Recruiting
Last Changed: Feb 01, 2019
First Received: Feb 23, 2017
Disease(s): B-cell Lymphoma
Intervention(s): AC0010MA
Locations: Peking Union Medical College Hospital, Beijing, Beijing, China
The First Affiliated Hospital,Zhejiang University, Hangzhou, Zhejiang, China
Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: May 01, 2018
First Received: May 01, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): (R)-CHOP regimen, (R)-CVP regimen
Locations: Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Status: Recruiting
Last Changed: Nov 14, 2017
First Received: Sep 04, 2015
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Bortezomib, Gemcitabine, Dexamethasone, Cisplatin
Locations: Ruijin Hospital, Shanghai, Shanghai, China
Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Aug 09, 2019
First Received: Oct 07, 2015
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation
Locations: University of Nebraska Medical Center, Omaha, Nebraska, United States
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
... and 10 other locations.